<DOC>
	<DOCNO>NCT01790022</DOCNO>
	<brief_summary>In study , efficacy methylprednisolone reduction sign symptom ( back pain , stiffness , joint pain swell ) active ankylose spondylitis ( AS ) investigate . It expect , single dose methylprednisolone 500 mg give intravenously baseline lead rapid reduction symptom active AS , see already 2 week drug administration .</brief_summary>
	<brief_title>Efficacy Safety MEthylprednisolone Administered Intravenously Treatment Patients With Active AnkyLosing spondyLitis ( METALL )</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Age ≥18 year . Definite diagnosis AS accord modify New York criterion . History inadequate response ≥2 nonsteroidal antiinflammatory drug ( NSAIDs ) take least 2 week NSAIDs intolerance . Active disease define Bath Ankylosing Spondylitis DIsease Activity Index ( BASDAI ) value ≥4 screen despite concomitant treatment NSAID without NSAIDs case intolerance . The female subject pregnant lactating . Patients chronic inflammatory articular disease systemic autoimmune disease . History inadequate response previous antitumour necrosis factor ( TNF ) α therapy . Treatment investigational drug within 4 week 5 halflife drug ( whichever longer ) prior baseline . Treatments disease modify antirheumatic drug ( DMARDs ) methotrexate within 4 week prior screen ( 8 week leflunomide 4 week standard cholestyramine washout ) . Treatment intravenous , intramuscular intraarticular/periarticular steroid within 4 week prior screen . History oesophageal , gastric , duodenal intestinal ulceration , clinically relevant gastrointestinal bleeding . History current sign coronary heart disease , myocardial infarction , stroke transient ischemic attack , peripheral arterial thrombotic event . Congestive heart failure ( NYHA IIIIV ) Uncontrolled arterial hypertension . History diabetes mellitus . History glaucoma . Major surgery within 12 week prior screen . Evidence severe uncontrolled gastrointestinal , hepatic , renal , pulmonary , cardiovascular , nervous endocrine disorder . Any active current viral , bacterial fungal infection , history recurrent clinically significant infection , infection require treatment antibiotic within 4 week prior baseline . History chronic infection hepatitis B C , history HIV infection . Primary secondary immunodeficiency . Any condition make patient unsuitable opinion investigator participation current study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>